Articles

Study finds drug combination increases costs and morbidity rates…. In a retrospective cohort study, researchers assessed Texas Medicare claims from 2006 to 2009 for patients 66 years or older who were prescribed glipizide or glyburide and who also filled a prescription for 1 of the 16 antimicrobials most commonly prescribed. …

Smoking during the first trimester may increase risk of type 2 diabetes later in life….

New study found low cognitive function may be a risk factor for diabetes…

Patients with type 2 diabetes and mild renal impairment experienced improved glycemic control when treated with ipragliflozin… According to lead author Atsunori Kashiwagi, MD, PhD, of Kusatsu General Hospital in Shiga, among patients with mild renal impairment, patients receiving ipragliflozin had a mean decrease in HbA1c of 0.56% at 6 …

Results show that a stricter target of 80-110 mg/dL is not superior to 110-140 mg/dL in mortality and morbidity rate…. Hyperglycemia is common among hospitalized patients; an intensive goal in hyperglycemia management of blood glucose is 80-110 mg/dL Studies have shown increased rates of hypoglycemia without morbidity and mortality with …

New phase 3a liraglutide 3 mg data showed weight-loss efficacy across a range of baseline BMI categories, and significant improvements in health-related quality of life… New data from the phase 3a SCALE™ (Satiety and Clinical Adiposity−Liraglutide Evidence in Non-diabetic and Diabetic people) Obesity and Pre-diabetes trial were presented at ObesityWeek. …

Manuka honey is produced in New Zealand by bees that pollinate the native manuka bush.

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …

The overall risk of metabolic syndrome decreased with every 100 mg per day increment in magnesium intake…. Previous studies have shown conflicting accounts of how beneficial dietary magnesium intake is in decreasing the risk of metabolic syndrome. The purpose of this meta-analysis was to determine the association between metabolic syndrome …

The addition of a DPP-4 inhibitor decreased HbA1C while not requiring an increase in insulin, and subjects remained weight neutral without experiencing an increase in hypoglycemic events… Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and …